Saran Malisorn

Efficacy and safety of generic alendronate for osteoporosis treatment

• Authors Details :  
• Saran Malisorn,  
• Atthakorn Jarusriwanna ,  
• Saran Malisorn ,  
• Sirikarn Tananoo ,  
• Kwanchanok Areewong,  
• Supachok Rasamimongkol,  
• Artit Laoruengthana

Journal title : Orthopedic Research and Reviews

Publisher : Informa UK Limited

Online ISSN : 1179-1462

Page Number : 85-91

Journal volume : Volume 16

36 Views Original Article

Background: While osteoporosis increases the risk of fragility fractures, bisphosphonate has been proven to increase bone strengthand reduce the risk of vertebral and non-vertebral fractures. In addition to its efficacy, substituting the brand with generic medication isa strategy to optimize healthcare expenditures. This study aimed to evaluate the efficacy of generic alendronate treatment and assesspotential adverse events in patients with osteoporosis.Materials and Methods: A retrospective review was conducted on 120 patients who met the indications for osteoporosis treatment,received weekly generic alendronate (70 mg) for >1 year, and underwent evaluation through standard axial dual-energy X-rayabsorptiometry (DXA). The outcomes of this study were the percent change in bone mineral density (BMD) at the lumbar spine,femoral neck, and total hip after one year of treatment. The major adverse events occurring during medication that led to thediscontinuation of drug administration were documented.Results: Most patients were female (96.7%) with an average age of 69.0 ± 9.3 years. The percent change in BMD increased at all sitesafter one year of generic alendronate treatment (lumbar spine: 5.6 ± 13.7, p-value <0.001; femoral neck: 2.3 ± 8.3, p-value = 0.023;total hip: 2.1 ± 6.2, p-value = 0.003), with over 85% of patients experiencing increased or stable BMD. Three patients discontinued themedication due to adverse effects: two had dyspepsia, and one had persistent myalgia.Conclusion: Generic alendronate may be considered an effective antiresorptive agent for osteoporosis treatment with a low incidenceof adverse effects

Article DOI & Crossmark Data

DOI : https://doi.org/10.2147/ORR.S445202

Article Subject Details

• Orthopaedics
• Orthopaedics Surgery
• Osteoporosis
• Osteoporosis with osteoporotic fractures
• Trauma

Article Keywords Details

• alendronate
• bisphosphonate
• bone mineral density
• fragility fracture
• Osteoporosis

Article File

Full Text PDF

Article References

• (1). 10.1016/j.clinthera.2015.06.006
• (2). 10.1007/s00198-008-0743-7
• (3). 10.1038/nrendo.2014.125
• (4). 10.1007/s11657-013-0136-1
• (5). 10.1002/jbmr.2269
• (6). 10.7326/0003-4819-137-6-200209170-00015
• (7). 10.1007/s00198-012-1931-z
• (8). 10.1359/jbmr.061113
• (9). 10.1002/jbmr.3051
• (10). 10.1056/NEJMcp1513724
• (11). 10.1016/j.bone.2016.05.013
• (12). 10.1371/journal.pone.0032879
• (13). 10.1016/j.afos.2016.07.001
• (14). 10.3389/fphar.2020.575893
• (15). 10.1371/journal.pone.0180325
• (16). 10.1185/03007995.2012.708326
• (17). 10.1186/2193-1801-2-550
• (18). 10.1016/j.afos.2023.06.001
• (19). 10.4158/GL-2020-0524SUPPL
• (20). 10.1136/bmjopen-2018-027049
• (21). 10.1007/s00198-014-2794-2
• (22). 10.1016/S0002-9343(01)01124-X
• (23). 10.1007/s00198-019-05258-2
• (24). Cost-utility analysis of treatment for prevention of osteoporotic fractures [Internet]. Nonthaburi (TH): Health Intervention and Technology Assessment Program; [cited August 8, 2023]. Available from: https://www.hitap.net/en/research/17703. Accessed February 16, 2024.
• (25). 10.1002/jbmr.119
• (26). 10.1016/S0149-2918(07)80087-7
• (27). 10.1111/os.13802
• (28). 10.1016/j.puhe.2023.10.022
• (29). 10.12336/biomatertransl.2022.03.002
• (30). 10.1126/sciadv.abb7135
• (31). 10.14740/jocmr2970w

---

More Article by Saran malisorn